Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisphosphonates for Post-Denosumab Bone Loss in IOP
NCT03396315Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jan 2018
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alendronate, zoledronic acid in idiopathic osteoporosis (IO), sponsored by Columbia University. Started Jan 2018; status: completed.
02
Drugs
alendronatezoledronic acid
03
Conditions
idiopathic osteoporosis (IO)
Beyond the preview
Go deeper on NCT03396315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03396315.